Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.

@article{Przuntek2002BudipinePA,
  title={Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.},
  author={Horst Przuntek and Stefan Bittkau and Harald Bliesath and Ulrich B{\"u}ttner and Gerd A. Fuchs and J Glass and Harald Haller and Thomas Klockgether and Peter Kraus and Lutz Lachenmayer and Dieter M{\"u}ller and Thomas M{\"u}ller and Bernhard Rathay and J{\"o}rg Sgonina and Volker W. Steinijans and Elemer Teshmar and Gudrun Ulm and Dieter Volc},
  journal={Archives of neurology},
  year={2002},
  volume={59 5},
  pages={
          803-6
        }
}
BACKGROUND The complex pharmacological profile of the antiparkinsonian drug budipine influences neurotransmission beyond the dopaminergic system. Previous studies have demonstrated the therapeutic efficacy of budipine on motor symptoms in insufficiently treated patients with Parkinson disease. OBJECTIVE To demonstrate the efficacy of 20 mg of budipine, 3 times daily, in addition to a stable, prior, optimum-titrated dopaminergic substitution consisting of a combination of levodopa and a dopa… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 16 REFERENCES

Nigral and extranigral pathology in Parkinson's disease.

  • Journal of neural transmission. Supplementum
  • 1995
VIEW 1 EXCERPT

Skalen und Scores in der Neurologie: Quantifizierung neurologischer Defizite in Forschung und Praxis

H. Masur
  • CME Announcement CME Hiatus: July Through December
  • 1995
VIEW 1 EXCERPT